ProKidney Corp. Files 8-K

Ticker: PROK · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1850270

Prokidney Corp. 8-K Filing Summary
FieldDetail
CompanyProkidney Corp. (PROK)
Form Type8-K
Filed DateSep 3, 2024
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-disclosure, 8-K, regulatory

TL;DR

ProKidney filed an 8-K on Sept 3rd, check for updates.

AI Summary

ProKidney Corp. filed an 8-K on September 3, 2024, reporting on events that occurred on the same date. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company was formerly known as Social Capital Suvretta Holdings Corp. III until a name change on March 10, 2021.

Why It Matters

This 8-K filing provides updates on ProKidney Corp.'s corporate activities and disclosures, which are important for investors to monitor the company's regulatory compliance and operational events.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information that would immediately impact risk.

Key Players & Entities

  • PROKIDNEY CORP. (company) — Registrant
  • Social Capital Suvretta Holdings Corp. III (company) — Former company name
  • September 3, 2024 (date) — Date of Report
  • March 10, 2021 (date) — Date of Name Change

FAQ

What is the primary purpose of this 8-K filing for ProKidney Corp.?

The primary purpose is to report on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits as of September 3, 2024.

When did ProKidney Corp. change its name?

ProKidney Corp. changed its name from Social Capital Suvretta Holdings Corp. III on March 10, 2021.

What is ProKidney Corp.'s principal executive office address?

The principal executive office is located at 2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, North Carolina, 27103.

What is the Commission File Number for ProKidney Corp.?

The Commission File Number for ProKidney Corp. is 001-40560.

What is the SIC code for ProKidney Corp.?

The Standard Industrial Classification (SIC) code for ProKidney Corp. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 1,320 words · 5 min read · ~4 pages · Grade level 15.6 · Accepted 2024-09-03 07:33:43

Key Financial Figures

  • $0.0001 — h registered Class A ordinary shares, $0.0001 par value per share PROK The Nasdaq

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. ProKidney Corp. (the "Company") has updated its investor presentation (the "Presentation"), which its senior management intends to use from time to time when interacting with investors and analysts, among others. The Presentation is available on the Company's website at https://investors.prokidney.com/news-events/events-and-presentations. The Presentation is also attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this Item 7.01 and Exhibit 99.1 of this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Item 7.01 and Exhibit 99.1 is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.

01 Other Events

Item 8.01 Other Events. On September 3, 2024, the Company issued a press release announcing strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentially preserve kidney function in patients with type 2 diabetes and advanced chronic kidney disease. A copy of the press release is filed as Exhibit 99.2 hereto and incorporated herein by reference. The disclosure in this report and the incorporated exhibits contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's beliefs that (i) rilparencel is eligible for initial FDA approval under an expedited approval pathway based upon the successful completion of the Phase 3 REGEN-006 (PROACT 1) trial, (ii) the Phase 3 REGEN-016 (PROACT 2) trial is not required for initial U.S. registration, and (iii) the revised Phase 3 program will accelerate estimated topline data readout and deliver topline results by Q3 2027, expectations with respect to financial results and expected cash runway, including the Company's expectation that current cash will support operating plans into Q1 2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company's products, if approved, potential regulatory approvals, the size and potential growth of current or future market

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation 99.2 Press Release dated September 3, 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROKIDNEY CORP. Date: September 3, 2024 By: /s/ James Coulston Name: James Coulston Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.